Wakako Maruyama
Research Subjects
Wakako Maruyama has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Makoto Naoi
Gifu International Institute of Biotechnology, Kakamigahara, Gifu, Japan
8 shared publications- Makoto Naoi
Gifu International Institute of Biotechnology
2 shared publications Takako Yamamoto
Nagoya University
2 shared publicationsToshihiko Osawa
Laboratory of Food and Biodynamics, Nagoya University Graduate School of Bioagricultural Sciences, Nagoya, Aichi, Japan
2 shared publications- Yoji Kato
School of Human Science and Environment
2 shared publications Keiko Inaba-Hasegawa
1 shared publication
Latest Publications
- 31 December 2010
- Published by Elsevier in Neuroscience Research
- Vol. 68, e71-e72
Neuroprotection by type B inhibitors is mediated by type A monoamine oxidase
- 31 December 2010
- Published by Elsevier in Neuroscience Research
- Vol. 68, e71-e72
Neuroprotection by type B inhibitors is mediated by type A monoamine oxidase
- 1 January 2006
- Published by Springer Nature
- Vol. 70 (70) , 125-132
The effect of neuromelanin on the proteasome activity in human dopaminergic SH-SY5Y cells.
- 1 January 2006
- Published by Springer Nature
- Vol. 70 (70) , 125-132
The effect of neuromelanin on the proteasome activity in human dopaminergic SH-SY5Y cells.
- 9 September 2004
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 4 (s1) , S194
Role of mitochondria in cell death of dopamine neurons in Parkinson disease
- 9 September 2004
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 4 (s1) , S194
Role of mitochondria in cell death of dopamine neurons in Parkinson disease
- 21 October 2003
- Published by Wiley in Journal of Neuroscience Research
- Vol. 74 (4) , 589-597
An inhibitor of mitochondrial complex I, rotenone, inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH‐SY5Y cells
In Parkinson's disease, characteristic pathological features are the cell death of nigrostriatal dopamine neurons and the formation of Lewy bodies composed of oxidized proteins. Mitochondrial dysfunction and aggregation of abnormal proteins have been proposed to cause the pathological changes. However, the relation between these two factors remains to be clarified. In this study, the effects of mitochondrial dysfunction on the oxidative modification and accumulation of proteins were analyzed using an inhibitor of mitochondrial complex I, rotenone, and antibodies against acrolein‐ and dityrosine‐modified proteins. Under conditions inducing mainly apoptosis in neuroblastoma SH‐SY5Y cells, rotenone markedly increased oxidized proteins, especially those modified with acrolein, even though the increase in intracellular reactive oxygen and nitrogen species was only transient and was not so marked. In addition, the activity of the proteasome system degrading oxidized proteins was reduced profoundly after treatment with rotenone. The 20S β subunit of proteasome was modified with acrolein, to which other acrolein‐modified proteins were found to bind, as shown by coprecipitation with the antibody against 20S β subunit. These results suggest that mitochondrial dysfunction, especially decreased activity of complex I, may reduce proteasome activity through oxidative modification of proteasome itself and aggregation with other oxidized proteins. This mechanism might account for the accumulation of modified protein and, at least partially, for cell death of the dopamine neurons in Parkinson's disease.
- 21 October 2003
- Published by Wiley in Journal of Neuroscience Research
- Vol. 74 (4) , 589-597
An inhibitor of mitochondrial complex I, rotenone, inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH‐SY5Y cells
In Parkinson's disease, characteristic pathological features are the cell death of nigrostriatal dopamine neurons and the formation of Lewy bodies composed of oxidized proteins. Mitochondrial dysfunction and aggregation of abnormal proteins have been proposed to cause the pathological changes. However, the relation between these two factors remains to be clarified. In this study, the effects of mitochondrial dysfunction on the oxidative modification and accumulation of proteins were analyzed using an inhibitor of mitochondrial complex I, rotenone, and antibodies against acrolein‐ and dityrosine‐modified proteins. Under conditions inducing mainly apoptosis in neuroblastoma SH‐SY5Y cells, rotenone markedly increased oxidized proteins, especially those modified with acrolein, even though the increase in intracellular reactive oxygen and nitrogen species was only transient and was not so marked. In addition, the activity of the proteasome system degrading oxidized proteins was reduced profoundly after treatment with rotenone. The 20S β subunit of proteasome was modified with acrolein, to which other acrolein‐modified proteins were found to bind, as shown by coprecipitation with the antibody against 20S β subunit. These results suggest that mitochondrial dysfunction, especially decreased activity of complex I, may reduce proteasome activity through oxidative modification of proteasome itself and aggregation with other oxidized proteins. This mechanism might account for the accumulation of modified protein and, at least partially, for cell death of the dopamine neurons in Parkinson's disease.
- 1 September 2002
- Published by Springer Nature in Journal of Neurology
- Vol. 249 (2) , 1
Cell death in Parkinson's disease
- 1 September 2002
- Published by Springer Nature in Journal of Neurology
- Vol. 249 (2) , 1
Cell death in Parkinson's disease
- 1 September 2002
- Published by Elsevier in Neurotoxicology and Teratology
- Vol. 24 (5) , 675-682
Neuroprotection by propargylamines in Parkinson's disease
- 1 September 2002
- Published by Elsevier in Neurotoxicology and Teratology
- Vol. 24 (5) , 675-682
Neuroprotection by propargylamines in Parkinson's disease
- 1 March 2002
- Published by Elsevier in Neuroscience Letters
- Vol. 321 (1-2) , 29-32
Glyceraldehyde-3-phospate dehydrogenase is translocated into nuclei through Golgi apparatus during apoptosis induced by 6-hydroxydopamine in human dopaminergic SH-SY5Y cells
- 1 March 2002
- Published by Elsevier in Neuroscience Letters
- Vol. 321 (1-2) , 29-32
Glyceraldehyde-3-phospate dehydrogenase is translocated into nuclei through Golgi apparatus during apoptosis induced by 6-hydroxydopamine in human dopaminergic SH-SY5Y cells
- 1 January 2001
- Published by Springer Nature in AGE
- Vol. 24 (1) , 11-18
Peroxynitrite induces neuronal cell death in aging and age-associated disorders: A review
- 1 January 2001
- Published by Springer Nature in AGE
- Vol. 24 (1) , 11-18
Peroxynitrite induces neuronal cell death in aging and age-associated disorders: A review
- 1 July 2000
- Published by Elsevier in Mechanisms of Ageing and Development
- Vol. 116 (2-3) , 181-191
Mechanism underlying anti-apoptotic activity of a (−)deprenyl-related propargylamine, rasagiline
- 1 July 2000
- Published by Elsevier in Mechanisms of Ageing and Development
- Vol. 116 (2-3) , 181-191
Mechanism underlying anti-apoptotic activity of a (−)deprenyl-related propargylamine, rasagiline
- Open Access
- 1 January 2000
- Published by Japanese Pharmacological Society in Folia Pharmacologica Japonica
- Vol. 116 (6) , 333-342
Studies on endogenous toxins as pathogenic factors in idiopathic Parkinson's disease.
孤発性パーキンソン病の原因は不明であるが,ヒト脳に内在するドパミン神経細胞に選択的な神経毒が関与している可能性が示唆されている.神経毒候補物質の中でも脳内でドパミンより2段階の酵素反応により生成されるN-methyl(R)salsolinol[NM(R)Sal]は in vivo においてラット脳黒質ドパミン神経細胞に選択的な毒性を示した.さらに,未治療パーキンソン病患者の脳脊髄液でNM(R)Sal濃度が増加していること,NM(R)Salはヒト脳黒質線条体に蓄積していることが示され,さらに脳内NM(R)Sal生成の律速段階は(R)サルソリノール中性N-メチル転移酵素[nNMT]であることが示唆された.リンパ球におけるnNMT活性を測定したところ,パーキンソン病患者では対照より有意に増加していた.nNMTの活性増加を引き起こす遺伝および環境要因がパーキンソン病の原因に関与している可能性がある.一方,パーキンソン病における神経細胞死はアポトーシスであるとの報告がなされているが,NM(R)Salはヒトドパミン神経芽細胞腫であるSH-SY5Y細胞にアポトーシスを惹起することが見い出された.アポトーシスの細胞内シグナルを検討したところ,ミトコンドリアの膜電位低下に引き続きカスパーゼ3の活性化と核の凝縮と分葉,DNAの断裂が認められた.さらに,NM(R)Salの光学異性体であるN-methyl(S)salsolinol[NM(S)Sal]はミトコンドリアの膜電位低下を惹起せず,アポトーシス誘導活性も殆ど認められなかった.ドパミン神経細胞ミトコンドリアにはNM(R)Salの光学異性体を認識し,アポトーシスを起動させる分子が存在する可能性がある.NM(R)Sal以外のパーキンソン病発症物質としては tetrahydroisoquinoline,β-カルボリン等が報告されているが,今後はこれら特定の物質に関する研究だけでなく,分子疫学的研究により孤発性パーキンソン病の原因を探究するとともに疾病を予防あるいは防御する治療法,特に経口投与可能な神経保護薬(抗アポトーシス薬)の開発が必要であろう.
- 1 January 2000
- Published by Japanese Pharmacological Society in Folia Pharmacologica Japonica
- Vol. 116 (6) , 333-342
Open AccessStudies on endogenous toxins as pathogenic factors in idiopathic Parkinson's disease.
孤発性パーキンソン病の原因は不明であるが,ヒト脳に内在するドパミン神経細胞に選択的な神経毒が関与している可能性が示唆されている.神経毒候補物質の中でも脳内でドパミンより2段階の酵素反応により生成されるN-methyl(R)salsolinol[NM(R)Sal]は in vivo においてラット脳黒質ドパミン神経細胞に選択的な毒性を示した.さらに,未治療パーキンソン病患者の脳脊髄液でNM(R)Sal濃度が増加していること,NM(R)Salはヒト脳黒質線条体に蓄積していることが示され,さらに脳内NM(R)Sal生成の律速段階は(R)サルソリノール中性N-メチル転移酵素[nNMT]であることが示唆された.リンパ球におけるnNMT活性を測定したところ,パーキンソン病患者では対照より有意に増加していた.nNMTの活性増加を引き起こす遺伝および環境要因がパーキンソン病の原因に関与している可能性がある.一方,パーキンソン病における神経細胞死はアポトーシスであるとの報告がなされているが,NM(R)Salはヒトドパミン神経芽細胞腫であるSH-SY5Y細胞にアポトーシスを惹起することが見い出された.アポトーシスの細胞内シグナルを検討したところ,ミトコンドリアの膜電位低下に引き続きカスパーゼ3の活性化と核の凝縮と分葉,DNAの断裂が認められた.さらに,NM(R)Salの光学異性体であるN-methyl(S)salsolinol[NM(S)Sal]はミトコンドリアの膜電位低下を惹起せず,アポトーシス誘導活性も殆ど認められなかった.ドパミン神経細胞ミトコンドリアにはNM(R)Salの光学異性体を認識し,アポトーシスを起動させる分子が存在する可能性がある.NM(R)Sal以外のパーキンソン病発症物質としては tetrahydroisoquinoline,β-カルボリン等が報告されているが,今後はこれら特定の物質に関する研究だけでなく,分子疫学的研究により孤発性パーキンソン病の原因を探究するとともに疾病を予防あるいは防御する治療法,特に経口投与可能な神経保護薬(抗アポトーシス薬)の開発が必要であろう.